Insulin remains the sole therapy for patients with type 1 diabetes (T1D), and despite advances in insulin development, iatrogenic hypoglycaemia remains a common problem for those patients seeking to reach optimal glycemic control. This evidence concerns the gene INS and type 1 diabetes mellitus.